We are only in part A of the phase. Dose escalation has not been trialled yet and we already have two patients with stable disease and one with a partial response to the drug. Part B explores efficacy due to dose escalation. Toxicity profile sounds positive for dose escalation. Our Part B is really a Phase 2 study on phase 1 part A patients, correct me if I am wrong.
Ann: Kazia releases preliminary Cantrixil Phase I data, page-15
-
- There are more pages in this discussion • 109 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)